PF06821497: Clinical Trials

2 recruiting, 1 active not recruiting. 3 Phase 3.

By phase and status

Phase	Trials	Status
Phase 3	3	Recruiting 2, Active not recruiting 1

Follow PF06821497: new trials by email Literature Review of PF06821497 trials Research Report on PF06821497

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. Mevrometostat, Placebo, Enzalutamide - Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer	Phase 3	Recruiting	Pfizer	1000	2025-09-28	2026-10-14
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. PF-06821497, Placebo, Enzalutamide - Metastatic Castration-Resistant Prostate Cancer	Phase 3	Recruiting	Pfizer	900	2024-10-22	2026-10-30
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). PF-06821497, Docetaxel, Enzalutamide - Metastatic Castrate Resistant Prostate Cancer (mCRPC)	Phase 3	Active not recruiting	Pfizer	609	2024-10-21	2026-10-30

Conditions studied

Prostatic Neoplasms (2)  ·  Recurrence (1)

Sponsors

Pfizer (3)

Countries

Argentina (3)  ·  Brazil (3)  ·  Canada (3)  ·  China (3)  ·  Czechia (3)  ·  France (3)  ·  Germany (3)  ·  Greece (3)  ·  Italy (3)  ·  Japan (3)  ·  Netherlands (3)  ·  Poland (3)  ·  Slovakia (3)  ·  South Korea (3)  ·  Spain (3)

Results publications

PMID 42108644